Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flindokalner. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 known ✓ | O43525 | 1/20 | 1.00 |
| ▸ | KCNQ2 known ✓ | O43526 | 1/20 | 1.00 |
| ▸ | KCNQ4 known ✓ | P56696 | 1/20 | 1.00 |
| ▸ | KCNMA1 known ✓ | Q12791 | 1/20 | 1.00 |
| ▸ | KCNQ5 known ✓ | Q9NR82 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flindokalner SCHEMBL29388740 | 1.00 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| Flindokalner SCHEMBL4877314 | 1.00 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| Flindokalner SCHEMBL30322726 | 1.00 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| Flindokalner SCHEMBL4056222 | 1.00 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL13139824 | 0.87 | KCNQ3 (0.77) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL24051652 | 0.86 | KCNQ3 (0.76) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL24051215 | 0.86 | KCNQ3 (0.76) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL24051653 | 0.86 | KCNQ3 (0.76) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL6130162 | 0.86 | KCNQ3 (0.76) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL5858002 | 0.85 | KCNQ3 (0.74) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478476-B2 | Use of buspirone metabolites | CONTERA PHARMA APS (DK) | 2022-10-25 | — | — | US | disclosed |
| US-10265300-B2 | Methods of treating seizure disorders | OVID THERAPEUTICS INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3160464-B1 | 6-HYDROXYBUSPIRONE FOR USE IN THE TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA APS (DK) | 2018-07-18 | — | — | EP | disclosed |
| US-20170128446-A1 | USE OF BUSPIRONE METABOLITES | CONTERA PHARMA APS (DK) | 2017-05-11 | — | — | US | disclosed |
| EP-3160464-A1 | USE OF BUSPIRONE METABOLITES | Contera Pharma APS (DK) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015197079-A1 | USE OF BUSPIRONE METABOLITES | CONTERA PHARMA APS (DK) | 2015-12-30 | — | — | WO | disclosed |
| EP-2729176-A1 | THE USE OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS | Contera Pharma APS (DK) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004249-A1 | THE USE OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS | CONCIT PHARMA APS (DK) | 2013-01-10 | — | — | WO | disclosed |
| EP-1485085-A4 | PHOSPHATE PRODRUGS OF FLUOROOXINDOLES | BRISTOL MYERS SQUIBB CO (US) | 2007-03-14 | — | — | EP | disclosed |
| US-6930100-B2 | Phosphate prodrugs of fluoroxindoles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-16 | — | — | US | disclosed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-1485085-A1 | PHOSPHATE PRODRUGS OF FLUOROOXINDOLES | Bristol-Myers Squibb Company (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20030195169-A1 | Phosphate prodrugs of fluorooxindoles | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-16 | — | — | US | disclosed |
| WO-2003080047-A1 | PHOSPHATE PRODRUGS OF FLUOROOXINDOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | KCNQ3 9/4885KCNQ2 6/4885KCNQ4 32/4885 |
| US-10265300-B2 | Methods of treating seizure disorders | KCNJ2, HCN2, CACNA1I | KCNQ3 7/4885KCNQ2 5/4885KCNQ4 19/4885 |
| US-20030195169-A1 | Phosphate prodrugs of fluorooxindoles | KCNA5, KCNN3, CACNA1E | KCNQ3 82/4885KCNQ2 67/4885KCNQ4 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.